Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients

@article{Anti2016DevelopmentAV,
  title={Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients},
  author={Darko Anti{\'c} and Natasa Milic and Srdjan Nikolovski and Milena Todorovi{\'c} and Jelena Bila and Predrag M. Djurdjevic and Bosko Andjelic and Vladislava T Djurasinovi{\'c} and Aleksandra Sretenovi{\'c} and Vojislav M. Vukovic and Jelena Jelicic and Suzanne R. Hayman and Biljana S. Mihaljevic},
  journal={American Journal of Hematology},
  year={2016},
  volume={91}
}
Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. We sought to develop and validate a simple model, based on individual clinical and laboratory patient characteristics that would designate lymphoma patients at risk for thromboembolic event. The study population included 1,820 lymphoma patients who were treated in the Lymphoma Departments at the Clinics of Hematology, Clinical Center of Serbia and Clinical Center… Expand
Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization
TLDR
A monocentric retrospective analysis of 857 adult patients with newly diagnosed lymphomas consecutively admitted and treated in the authors' center from 2004 to 2015, and having had at least one hospital stay to determine the incidence of VTE and to identify lymphoma-specific risk factors. Expand
Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis
TLDR
Knowledge of VTE risk factors in lymphomas may help in the evaluation of the individual risk-benefit ratio of prophylaxis and help to design prospective studies on primary proPHylaxis in lymphoma. Expand
The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma.
  • H. Abdel-Razeq, M. Ma’koseh, +8 authors M. Zmaily
  • Medicine
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2021
TLDR
ThroLy RAM can identify patients with DLBCL at high risk for VTE and can be modified by dividing patients into two, rather than three risk groups, and further simplified by omitting neutropenia. Expand
Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma.
TLDR
Results show that by incorporating genetic and clinical data into VTE risk assessment, the TiC-LYMPHO score can categorize patients with lymphoma better in terms of their risk of VTE and allow individualized thromboprophylaxis to be prescribed. Expand
Venous thromboembolic events in T-cell lymphoma patients: Incidence, risk factors and clinical features.
TLDR
The incidence of VTE in the present study population was comparable to that of lymphoma patients, other than T-cell lymphoma, and VTE was associated with CVC and advanced stage. Expand
Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice
TLDR
The ThroLy score was not a suitably accurate model for predicting VTE events in patients at higher risk of VTE and further research should be conducted to identify new biomarkers that will predict these events and to establish a new VTE risk assessment model. Expand
Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score
TLDR
In this cohort of patients with lymphoid malignancies, the KRS did not adequately stratify or predict VTE events in patients at a higher risk of VTE, suggesting the need for the development of a disease-specific VTE assessment model. Expand
Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment.
TLDR
The lack of adequate guidelines for the prophylaxis and treatment of VTE in lymphoma patients, together with a cautious approach due to an increased risk of bleeding, demands great efforts to ensure the implementation of current knowledge in order to reduce the incidence and complications of Vte in lymph cancer patients. Expand
Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy.
  • J. Byun, Junshik Hong, +11 authors Doyeun Oh
  • Medicine
  • Thrombosis research
  • 2019
TLDR
The incidence of VTE in Asian PCNSL seems to be lower compared to Western population, and as VTE development is associated with overall survival and indicative of relapse, careful close monitoring is warranted. Expand
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models
TLDR
The Khorana risk‐score was validated in time to event analyses, and a more robust lymphoma‐specific VTE risk score is proposed, to suggest lymphoma patients with highest VTErisk can be identified with baseline parameters. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 51 REFERENCES
Development and validation of a predictive model for chemotherapy-associated thrombosis.
TLDR
A simple model for predicting chemotherapy-associated venous thromboembolism using baseline clinical and laboratory variables can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis. Expand
Incidence and risk factors of venous thromboembolic events in lymphoma.
TLDR
Lymphoma patients are at high risk for venous thromboembolism in the initial cycles of chemotherapy; the risk was higher for women, patients with elevated hemoglobin or creatinine, or those receiving doxorubicin or methotrexate. Expand
Thromboembolism in hospitalized neutropenic cancer patients.
PURPOSE Cancer is associated with thrombosis, but the frequency of thromboembolism in hospitalized cancer patients receiving current chemotherapy regimens is not known. We investigated venous andExpand
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management.
TLDR
A gulf exists between current recommendations and clinical practice; greater efforts are required to ensure effective implementation of strategies to reduce the incidence of vte in patients with cancer. Expand
Venous thromboembolism in the hematologic malignancies.
  • A. Falanga, M. Marchetti
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
Large, prospective, randomized clinical trials are needed to establish the best practice for thromboprophylaxis and treatment of venous thromboembolism in acute leukemia, lymphomas, and multiple myeloma. Expand
Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.
TLDR
This meta-analysis shows that the IR of thrombosis in lymphoma patients is quite high, especially in those with NHL at an advanced stage of the disease, to whom prophylactic approaches could be preferentially applied. Expand
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score
TLDR
The adoption of adequate thromboprophylaxis in high‐risk patients during hospitalization leads to longstanding protection against thromboembolic events with a low risk of bleeding. Expand
Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
TLDR
Patients with cancer have a highly increased risk of venous thrombosis especially in the first few months after diagnosis and in the presence of distant metastases, which is a common complication in patients with cancer. Expand
Incidence of venous thromboembolism and its effect on survival among patients with common cancers.
TLDR
For some types of cancer, the incidence of venous thromboembolism was sufficiently high to warrant prospective clinical trials of primary thromboprophylaxis and was highest among patients initially diagnosed with metastatic-stage disease. Expand
Outcomes and cost of deep venous thrombosis among patients with cancer.
TLDR
More effective agents and less costly management strategies could have a significant impact on the outcomes and cost of DVT in this population of cancer patients. Expand
...
1
2
3
4
5
...